Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...

GCI Health has announced the appointment of Annalise Coady as president, UK market lead and EMEA head of growth. Coady brings ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...

UCB has announced “encouraging data” from a phase 2a study of its investigational anti-tau antibody bepranemab in Alzheimer’s ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

Knowing this, it amazes me how many pharmaceutical organisations of all sizes are missing the mark on key areas of launch ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a deal worth $1.3bn. The agreement gives Merck access to preclinical compounds ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience pipeline. The deal gives AbbVie access to Aliada’s therapies that use a novel ...